Literature DB >> 3621956

Extracorporeal membrane oxygenation and high-frequency oscillatory ventilation: potential therapeutic relationships.

J D Cornish, D R Gerstmann, R H Clark, J M Carter, D M Null, R A deLemos.   

Abstract

Eighteen neonates 33 to 42 wk gestational age with severe respiratory failure were referred for extracorporeal membrane oxygenation (ECMO). Sixteen ultimately met the ECMO criteria, of whom 15 were first offered high-frequency oscillatory ventilation (HFOV). Seven responded to HFOV alone and did not require ECMO treatment. Eight of the nine remaining patients were placed on ECMO support with HOFV. Infants who responded to HFOV alone tended to have pneumonia more than meconium aspiration, to be smaller and more immature, to have higher Apgar scores, and to have suffered severe hypoxia (alveolar-arterial oxygen pressure difference over 600 torr) for less time than the ECMO group. Although patient numbers are small, a trend is noted which favors HFOV treatment alone in terms of the duration of HFOV, the total duration of assisted ventilation, the rapidity with which extubation was accomplished, and the length of hospital stay.

Entities:  

Mesh:

Year:  1987        PMID: 3621956     DOI: 10.1097/00003246-198709000-00006

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  3 in total

1.  Entry criteria for extracorporeal membrane oxygenation In neonates with congenital diaphragmatic hernia treated with high-frequency oscillatory ventilation.

Authors:  S Kamata; Y Kitayama; H Okuyama; N Usui; T Sawai; S Ishikawa; K Imura; A Okada
Journal:  Pediatr Surg Int       Date:  1996-10       Impact factor: 1.827

Review 2.  Extracorporeal gas exchange in acute respiratory failure.

Authors:  K L Dorrington
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-16

3.  High frequency oscillatory ventilation and extracorporeal membrane oxygenation in severe persistent pulmonary hypertension of the newborn.

Authors:  V Varnholt; P Lasch; G Suske; W Kachel; W Brands
Journal:  Eur J Pediatr       Date:  1992-10       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.